PT3060660T - Glicoproteínas recombinantes e seus usos - Google Patents

Glicoproteínas recombinantes e seus usos

Info

Publication number
PT3060660T
PT3060660T PT147963466T PT14796346T PT3060660T PT 3060660 T PT3060660 T PT 3060660T PT 147963466 T PT147963466 T PT 147963466T PT 14796346 T PT14796346 T PT 14796346T PT 3060660 T PT3060660 T PT 3060660T
Authority
PT
Portugal
Prior art keywords
recombinant glycoproteins
glycoproteins
recombinant
Prior art date
Application number
PT147963466T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of PT3060660T publication Critical patent/PT3060660T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70592—CD52
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022—Alpha-galactosidase (3.2.1.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
PT147963466T 2013-10-23 2014-10-22 Glicoproteínas recombinantes e seus usos PT3060660T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361894879P 2013-10-23 2013-10-23
US201361901942P 2013-11-08 2013-11-08

Publications (1)

Publication Number Publication Date
PT3060660T true PT3060660T (pt) 2021-08-06

Family

ID=51871299

Family Applications (1)

Application Number Title Priority Date Filing Date
PT147963466T PT3060660T (pt) 2013-10-23 2014-10-22 Glicoproteínas recombinantes e seus usos

Country Status (33)

Country Link
US (2) US11208644B2 (enExample)
EP (2) EP3060660B1 (enExample)
JP (2) JP6837334B2 (enExample)
KR (2) KR102298080B1 (enExample)
CN (3) CN112852784A (enExample)
AU (2) AU2014340152A1 (enExample)
BR (1) BR112016008086A2 (enExample)
CA (1) CA2927852A1 (enExample)
CL (1) CL2016000961A1 (enExample)
CR (1) CR20160225A (enExample)
DK (1) DK3060660T3 (enExample)
DO (1) DOP2016000079A (enExample)
EA (1) EA034515B1 (enExample)
ES (1) ES2882562T3 (enExample)
HR (1) HRP20211197T1 (enExample)
HU (1) HUE055236T2 (enExample)
IL (2) IL245255B (enExample)
LT (1) LT3060660T (enExample)
MX (1) MX392532B (enExample)
MY (2) MY197247A (enExample)
NZ (1) NZ720384A (enExample)
PE (1) PE20160723A1 (enExample)
PH (1) PH12016500708B1 (enExample)
PL (1) PL3060660T3 (enExample)
PT (1) PT3060660T (enExample)
RS (1) RS62171B1 (enExample)
SG (2) SG11201602932WA (enExample)
SI (1) SI3060660T1 (enExample)
TN (1) TN2016000140A1 (enExample)
TW (3) TWI793159B (enExample)
UA (1) UA119857C2 (enExample)
UY (1) UY35794A (enExample)
WO (1) WO2015061464A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
JP7114485B2 (ja) * 2016-05-18 2022-08-08 モデルナティエックス インコーポレイテッド ファブリー病の治療のためのα-ガラクトシダーゼAをコードするポリヌクレオチド
KR102712926B1 (ko) 2016-10-20 2024-10-07 상가모 테라퓨틱스, 인코포레이티드 파브리병의 치료를 위한 방법 및 조성물
US11357834B2 (en) 2017-01-10 2022-06-14 Amicus Therapeutics, Inc. Recombinant α-galactosidase A for treatment of Fabry disease
CN113423419A (zh) 2019-01-04 2021-09-21 桑格摩生物治疗股份有限公司 用于治疗法布里病的方法和组合物
WO2025092951A1 (en) * 2023-11-03 2025-05-08 Shanghai Vitalgen Biopharma Co., Ltd. Recombinant adeno-associated viral vectors for treating fabry disease

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5401650A (en) 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
US5356804A (en) * 1990-10-24 1994-10-18 Mount Sinai School Of Medicine Of The City Of New York Cloning and expression of biologically active human α-galactosidase A
US6458574B1 (en) * 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
US6083725A (en) 1996-09-13 2000-07-04 Transkaryotic Therapies, Inc. Tranfected human cells expressing human α-galactosidase A protein
NZ506214A (en) * 1996-09-13 2002-11-26 Transkaryotic Therapies Inc Therapy for alpha-galactosidase A deficiency
EP1027069B1 (en) 1997-10-29 2006-07-26 Genzyme Corporation Gene therapy for gaucher disease
US20020081654A1 (en) * 2000-04-07 2002-06-27 Sandrin Mauro Sergio Targeting hydrolase enzymes
US7138262B1 (en) * 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
US7133354B2 (en) 2002-08-26 2006-11-07 Qualcomm Incorporated Synchronization techniques for a wireless system
TWI328614B (en) * 2002-12-23 2010-08-11 Bristol Myers Squibb Co Product quality enhancement in mammalian cell culture processes for protein production
CN100522988C (zh) * 2003-04-09 2009-08-05 诺和诺德公司 糖peg化方法及由该方法生产的蛋白质/肽
JP5967861B2 (ja) * 2007-04-03 2016-08-10 オキシレイン ユーケー リミテッド 分子のグリコシル化
US20110117601A1 (en) * 2007-08-31 2011-05-19 Markus Haberger Glycosylation Profile Analysis
US9034341B2 (en) * 2009-04-20 2015-05-19 Transtech Pharma, Llc Control of RAGE fusion protein glycosylation and RAGE fusion protein compositions
DK2865751T3 (en) * 2010-03-02 2017-01-09 Protalix Ltd Stabilized alpha-galactosidase and uses thereof
US20120178105A1 (en) 2011-01-10 2012-07-12 Genzyme Corporation Detection of globotriaosylceramide (glc) in human urine samples using an antibody sandwich
EP2665814B1 (en) * 2011-01-20 2017-05-17 Protalix Ltd. Nucleic acid construct for expression of alpha-galactosidase in plants and plant cells
WO2013055888A2 (en) * 2011-10-12 2013-04-18 Synageva Biopharma Corp. Recombinant human naglu protein and uses thereof
EP2620506A1 (en) 2012-01-25 2013-07-31 Arla Foods Amba Method of producing a galacto-oligosaccharide-containing composition
TWI528785B (zh) 2013-02-08 2016-04-01 瑞昱半導體股份有限公司 立體影像的調整裝置及其方法
AU2014226126B2 (en) 2013-03-08 2019-02-14 Genzyme Corporation Continuous purification of therapeutic proteins

Also Published As

Publication number Publication date
CR20160225A (es) 2016-06-24
TW201900873A (zh) 2019-01-01
TW201610163A (zh) 2016-03-16
US11208644B2 (en) 2021-12-28
AU2020294173A1 (en) 2021-02-11
UA119857C2 (uk) 2019-08-27
JP7296327B2 (ja) 2023-06-22
AU2014340152A1 (en) 2016-06-09
TN2016000140A1 (en) 2017-10-06
SG11201602932WA (en) 2016-05-30
CN114606217A (zh) 2022-06-10
MY197247A (en) 2023-06-08
MX2016005321A (es) 2017-01-05
RS62171B1 (sr) 2021-08-31
UY35794A (es) 2015-05-29
IL272609B (en) 2022-03-01
LT3060660T (lt) 2021-07-26
IL272609A (en) 2020-03-31
KR102298080B1 (ko) 2021-09-06
CL2016000961A1 (es) 2017-02-03
KR102479886B1 (ko) 2022-12-20
SG10201803366PA (en) 2018-05-30
JP6837334B2 (ja) 2021-03-03
DOP2016000079A (es) 2016-05-30
MX392532B (es) 2025-03-24
DK3060660T3 (da) 2021-09-13
WO2015061464A2 (en) 2015-04-30
PH12016500708B1 (en) 2023-03-01
KR20160066550A (ko) 2016-06-10
EP3060660B1 (en) 2021-06-23
ES2882562T3 (es) 2021-12-02
TWI793159B (zh) 2023-02-21
TWI642782B (zh) 2018-12-01
TW202332774A (zh) 2023-08-16
JP2016538840A (ja) 2016-12-15
EP3060660A2 (en) 2016-08-31
JP2020089379A (ja) 2020-06-11
NZ720384A (en) 2022-04-29
MY178632A (en) 2020-10-19
EA201690826A1 (ru) 2016-08-31
US20220064617A1 (en) 2022-03-03
EA034515B1 (ru) 2020-02-14
EP3778884A1 (en) 2021-02-17
CA2927852A1 (en) 2015-04-30
KR20210111880A (ko) 2021-09-13
PE20160723A1 (es) 2016-08-01
SI3060660T1 (sl) 2021-09-30
PH12016500708A1 (en) 2016-05-30
CN112852784A (zh) 2021-05-28
HUE055236T2 (hu) 2021-11-29
US20160264953A1 (en) 2016-09-15
WO2015061464A3 (en) 2015-09-03
CN105916984A (zh) 2016-08-31
BR112016008086A2 (pt) 2017-10-03
PL3060660T3 (pl) 2021-12-06
IL245255A0 (en) 2016-06-30
IL245255B (en) 2020-02-27
HRP20211197T1 (hr) 2021-11-12

Similar Documents

Publication Publication Date Title
IL276106A (en) Garp-binding proteins and their uses
IL244810A0 (en) Stabilized polypeptides and their uses
PL3686280T3 (pl) Polipeptyd degradujący węglowodany i jego zastosowania
ZA201505966B (en) Peptides and compositions
GB201306536D0 (en) Polypeptide and immune modulation
PT3058936T (pt) Composição peptídica e respetivos usos
IL240527B (en) Composition of dentures and denture system
IL320195A (en) Methods and compositions containing purified recombinant polypeptides
GB201321693D0 (en) Composition and uses thereof
GB201305277D0 (en) Novel combination and use
IL272609B (en) Recombinant glycoproteins and their uses
SMT201800545T1 (it) Peptide antimicrobico e suoi usi
GB201304973D0 (en) Recombinant protein
EP3046929A4 (en) Erk-derived peptides and uses thereof
ZA201601880B (en) Hetero-transglycosylase and uses thereof
GB201320992D0 (en) Complex and uses thereof
EP2957953A4 (en) CAMERA AND CAMERA ARRANGEMENT
EP2970349A4 (en) Carbohydrate-modified glycoproteins and uses thereof
PL2821730T3 (pl) Złączka z zestawem montażowym
GB201305297D0 (en) Novel agents and uses thereof
HK1226444A1 (zh) 重組糖蛋白及其用途
GB201312948D0 (en) Glycoproteins
EP3006564A4 (en) NEW PEPTIDE AND ITS USE
GB201304166D0 (en) CelebQuiff and Instant Quiff
GB201301640D0 (en) Methods and peptides